Larimar Therapeutics Inc (LRMR) is trading down at $2.27 (-6.20%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — |
| Operating income | −$58.2M | −$53.0M | −$61.1M | −$23.2M | −$42.8M | −$50.5M | −$36.5M | −$41.8M | −$90.9M | −$172.5M |
| Net income | −$57.9M | −$52.0M | −$61.4M | −$23.1M | −$42.5M | −$50.6M | −$35.4M | −$36.9M | −$80.6M | −$165.7M |
| EPS (diluted) | −$135.68 | −$121.60 | −$121.60 | −$3.80 | −$3.57 | −$2.95 | −$1.37 | −$0.84 | −$1.32 | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $32.4M | $40.8M | $49.3M | $1.01M | $68.1M | $70.1M | $26.8M | $26.7M | $33.2M | $85.4M |
| Total assets | $131.6M | $105.5M | $121.8M | $5.20M | $104.7M | $78.7M | $126.4M | $95.9M | $200.2M | $145.8M |
| Total liabilities | $9.89M | $27.3M | $28.5M | $5.89M | $15.0M | $14.3M | $15.5M | $14.2M | $28.4M | $67.8M |
| Long-term debt | $3.18M | $20.0M | $20.0M | $14.5M | — | — | — | — | — | — |
| Shareholders' equity | $121.7M | $78.2M | $2.91M | −$694.0K | $89.7M | $64.4M | $110.9M | $81.7M | $171.8M | $78.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$52.0M | −$43.8M | −$51.5M | −$22.7M | −$42.2M | −$42.1M | −$27.6M | −$33.5M | −$70.8M | −$113.2M |
| Capital expenditure | $660.0K | $55.0K | $108.0K | $83.0K | $62.0K | $333.0K | $100.0K | $164.0K | $515.0K | $91.0K |
| Free cash flow | −$52.6M | −$43.8M | −$51.6M | −$22.8M | −$42.3M | −$42.4M | −$27.7M | −$33.6M | −$71.3M | −$113.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$18.3M | −$31.3M | −$31.2M | −$27.8M | −$49.5M | −$64.0M | −$31.1M | −$34.4M |
| Net income | −$15.5M | −$28.8M | −$29.3M | −$26.2M | −$47.7M | −$62.5M | −$29.6M | −$32.8M |
| EPS (diluted) | −$0.24 | −$0.47 | −$0.46 | −$0.41 | −$0.61 | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $35.1M | $33.2M | $21.1M | $20.6M | $90.1M | $85.4M | $177.9M | $92.7M |
| Total assets | $219.0M | $200.2M | $170.2M | $150.0M | $187.3M | $145.8M | $208.5M | $165.3M |
| Total liabilities | $20.6M | $28.4M | $25.9M | $30.1M | $48.3M | $67.8M | $50.5M | $37.9M |
| Shareholders' equity | $198.4M | $171.8M | $144.3M | $119.9M | $139.0M | $78.1M | $158.0M | $127.4M |
| Cash flow | ||||||||
| Operating cash flow | −$24.5M | −$21.8M | −$26.5M | −$19.4M | — | — | −$44.6M | −$44.0M |
| Capital expenditure | $62.0K | $179.0K | $49.0K | $19.0K | $23.0K | $0 | — | — |
| Free cash flow | −$24.6M | −$22.0M | −$26.6M | −$19.4M | — | — | — | — |
From Larimar Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Larimar Therapeutics Inc in our feed yet.